Current Report Filing (8-k)
January 17 2023 - 8:52AM
Edgar (US Regulatory)
0000946644
false
0000946644
2023-01-13
2023-01-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
January
13, 2023
AIM
IMMUNOTECH INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-27072 |
|
52-0845822 |
(state
or other jurisdiction |
|
(Commission |
|
(I.R.S.
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
2117
SW Highway 484, Ocala FL |
|
34473 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (352) 448-7797
AIM
ImmunoTech Inc.
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
AIM |
|
NYSE
American |
Item
1.01 Entry into a Material Definitive Agreement.
On
January 13, 2023, we entered into an external sponsored collaborative clinical research agreement with Erasmus University Medical Center
Rotterdam and AstraZeneca BV, pursuant to which Erasmus is sponsoring and planning to perform an investigator-initiated clinical study,
entitled Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic
ductal adenocarcinoma for therapy effect (the “Study”) in which it will use both study drugs provided by AstraZeneca
and us. We also have entered into an Investigator Initiated Study Support Agreement (the “Support Agreement”) with Erasmus
regarding the Study. We anticipate that the Study will be a phase II, non-randomized, open-label, single-arm, single center study with
two subsequent phases pursuant to the protocol set forth in the Support Agreement. We will supply Erasmus with a sufficient supply of
rintatolimod to conduct the Study and AstraZeneca will supply the durvalumab. We retain all rights to our intellectual property. Erasmus
will own all right to the Study data but shall permit us to use the Study Data for any purpose. We shall own all rights and titles to
inventions arising from the Study related to rintatolimod. The Study Agreement is terminable upon the completion of the Study or upon
the happening of certain events including the insolvency of a party, a material breach which is not remedied within 30 days after notice,
the Study not receiving official approval from the Ethics Committee or competent authorities or the approval being permanently revoked,
or force majeure.
Cautionary
Statement
This
Current Report on Form 8-K and the exhibit filed herewith, contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,”
“anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are
intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties.
Among other things, for those statements, we claim the protection of safe harbor for forward-looking statements contained in the PSLRA.
Any forward-looking statements set forth herein speak only as of the date hereof. We do not undertake to update any of these forward-looking
statements to reflect events or circumstances that occur after the date hereof. No assurance can be given as to whether the Study will
be successful, yield favorable data or not require additional funding, and the Study is subject to many factors. Operating in foreign
countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. We cannot assure
that our potential foreign operations will not be adversely affected by these risks.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIM
IMMUNOTECH INC. |
|
|
|
January
17, 2023 |
By: |
/s/
Thomas K. Equels |
|
|
Thomas
K. Equels, CEO |
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
AIM ImmunoTech (AMEX:AIM)
Historical Stock Chart
From Sep 2023 to Sep 2024